MX2024012608A - Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav - Google Patents
Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raavInfo
- Publication number
- MX2024012608A MX2024012608A MX2024012608A MX2024012608A MX2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A
- Authority
- MX
- Mexico
- Prior art keywords
- optimization
- suspension platform
- improved raav
- hek293 suspension
- raav titers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329856P | 2022-04-11 | 2022-04-11 | |
| US202263331438P | 2022-04-15 | 2022-04-15 | |
| PCT/US2023/017838 WO2023200679A1 (en) | 2022-04-11 | 2023-04-07 | OPTIMIZATION OF HEK293 SUSPENSION PLATFORM FOR IMPROVED rAAV TITERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012608A true MX2024012608A (es) | 2024-11-08 |
Family
ID=88330208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012608A MX2024012608A (es) | 2022-04-11 | 2024-10-10 | Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250250547A1 (https=) |
| EP (1) | EP4508198A4 (https=) |
| JP (1) | JP2025512382A (https=) |
| KR (1) | KR20250004745A (https=) |
| CN (1) | CN119053692A (https=) |
| AU (1) | AU2023254746A1 (https=) |
| CA (1) | CA3245930A1 (https=) |
| MX (1) | MX2024012608A (https=) |
| WO (1) | WO2023200679A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4683041A1 (en) | 2024-02-29 | 2026-01-21 | LG Energy Solution, Ltd. | Method for regenerating cathode active material, and regenerated cathode active material prepared thereby |
| WO2026013235A1 (en) * | 2024-07-11 | 2026-01-15 | Ferring International Center S.A. | Methods of producing recombinant adenovirus vectors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208315B2 (en) * | 2000-01-05 | 2007-04-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for efficient AAV vector production |
| US20140315294A1 (en) * | 2011-11-24 | 2014-10-23 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| CA3130108A1 (en) * | 2019-02-22 | 2020-08-27 | Life Technologies Corporation | Suspension system for adeno associated virus production |
-
2023
- 2023-04-07 AU AU2023254746A patent/AU2023254746A1/en active Pending
- 2023-04-07 WO PCT/US2023/017838 patent/WO2023200679A1/en not_active Ceased
- 2023-04-07 CA CA3245930A patent/CA3245930A1/en active Pending
- 2023-04-07 EP EP23788783.1A patent/EP4508198A4/en active Pending
- 2023-04-07 CN CN202380033234.3A patent/CN119053692A/zh active Pending
- 2023-04-07 KR KR1020247037355A patent/KR20250004745A/ko active Pending
- 2023-04-07 US US18/855,209 patent/US20250250547A1/en active Pending
- 2023-04-07 JP JP2024560323A patent/JP2025512382A/ja active Pending
-
2024
- 2024-10-10 MX MX2024012608A patent/MX2024012608A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4508198A1 (en) | 2025-02-19 |
| KR20250004745A (ko) | 2025-01-08 |
| EP4508198A4 (en) | 2026-04-22 |
| CA3245930A1 (en) | 2023-10-19 |
| US20250250547A1 (en) | 2025-08-07 |
| WO2023200679A1 (en) | 2023-10-19 |
| JP2025512382A (ja) | 2025-04-17 |
| CN119053692A (zh) | 2024-11-29 |
| AU2023254746A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012608A (es) | Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav | |
| Kaneda et al. | PI3Kγ is a molecular switch that controls immune suppression | |
| BR112012011529A2 (pt) | sistema de laser, e, método para escanear um feixe de laser | |
| WO2020198509A3 (en) | Modified oligonucleotides with increased stability | |
| Herdy et al. | The RNA‐binding protein HuR/ELAVL1 regulates IFN‐β mRNA abundance and the type I IFN response | |
| NO20074911L (no) | Behandling av benforstyrrelser | |
| BR112018076281A2 (pt) | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo | |
| BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
| PL439808A1 (pl) | Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| NO20080246L (no) | Anti-IGF1R-antistofformuleringer | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| BR112022018254A2 (pt) | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo | |
| BR112022015601A2 (pt) | Grandes vetores genéticos e dispensação e usos dos mesmos | |
| PH12021552176A1 (en) | Antibodies and methods for treatment of influenza a infection | |
| BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
| BR112022001329A2 (pt) | Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo | |
| JOP20250152A1 (ar) | الفيروس المحلل للورم واستخداماته | |
| PH12020551642A1 (en) | Aav compositions, methods of making and methods of use | |
| BR112018010669A2 (pt) | anticorpo anti-pcsk9 e utilização do mesmo | |
| WO2024227174A3 (en) | Antibodies that bind ox40l and methods of use | |
| JOP20190179A1 (ar) | نوكليوتيدات ثنائية حلقية كناهضات لـ sting | |
| AU2017261305A8 (en) | DNA monoclonal antibodies targeting influenza virus | |
| CL2025001926A1 (es) | Anticuerpo anti-tgfß3; anticuerpo anti-tgfß2/3; anticuerpo anti-tgfß2; método de producción; y su uso. |